Effects of the treatment with the anti-inflamatory medication AP1189 on the lung involvement in COVID-19 patients with impaired breathing.
- Conditions
- Severe acute respiratory syndrome
- Registration Number
- RBR-59447vn
- Lead Sponsor
- niversidade Federal de Minas Gerais
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Male and female subjects, 18 to 85 years of age hospitalized with COVID-19 infection; Written informed consent; Confirmed COVID-19 by the presence of SARS-CoV-2 nucleic acid by polimerase chain reaction; Pregnancy is excluded or unlikely (reliable contraception/post-menopausal women).
Progress to death is imminent and unavoidable in the opinion of the investigator; Participating in other clinical trials (except in COVID-19 antiviral drug trials); Any condition that in the view of the screening physician suggests that the patient is unable to comply with study procedures; Subjects treated with immunosuppressive drugs; HIV infection; Pregnant women or breastfeeding mothers; Estimated glomerular filtration rate less than 30ml/min; Severe liver disfunction (Child-Pugh score C); Medical history of oral glucocorticoid treatment (Exception is COVID-19 dexamethasone treatment not exceeding 10mg/day).
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method